Full-Time

Research Associate

Drug Discovery

General Proximity

General Proximity

11-50 employees

Seed-stage platform for induced proximity drugs

No salary listed

San Francisco, CA, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Biochemistry
Data Analysis
Requirements
  • BS or MS in Biology, Biochemistry, Molecular Biology, or a related field.
Responsibilities
  • Designing and executing experiments independently or in collaboration with senior researchers.
  • Contributing to the development and optimization of experimental protocols and assays.
  • Preparation and handling of biological samples including mammalian cell cultures.
  • Performing advanced laboratory techniques and methodologies.
  • Data analysis and interpretation under the guidance of senior researchers.
  • Recording and organizing experimental data accurately and efficiently.
Desired Qualifications
  • Industry experience is desirable.
  • Deep understanding of small-molecule drug discovery and its relationship to human disease.
  • Top-notch written and oral communication skills.
  • Proficiency in: Mammalian cell culture, passaging/seeding cells, aseptic technique; Molecular biology/cloning, PCR, and other common biology techniques like western blotting, flow cytometry, microscopy, and biochemical assays; Assay development and optimization; Strong understanding of basic biological principles and laboratory techniques; Strong problem-solving skills and the ability to work independently as well as part of a team.
  • 2+ years of post-degree experience;
  • Experience with HTS and phenotypic cell-based assay development;
  • Transient/stable protein expression and purification, immunoprecipitation assays;
  • Experience working with CRISPR-Cas systems;
  • Familiarity with data analysis software (e.g., Prism) and statistical tools;
  • Familiarity with automatic, robotic dispensers, liquid handlers;
  • Prior experience on teams that have successfully advanced research to the clinic

Preparing a concise company summary based on provided description.

Company Size

11-50

Company Stage

Seed

Total Funding

$16.1M

Headquarters

San Francisco, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Daiichi Sankyo collaboration advances OmniTAC oncology candidates via Boston institute.
  • Daewoong Pharmaceutical investment funds induced proximity drugs for cardiovascular and neurodegenerative diseases.
  • $16M seed from Felicis, Y Combinator accelerates $250B market undruggable targets.

What critics are saying

  • Cash from $16M seed exhausts by mid-2026 without Series A proof-of-concept.
  • Daiichi Sankyo exclusivity blocks Arvinas-competing deals for 12-18 months.
  • Novartis poaches Scripps scientists like Andreas Maderna within 6-12 months.

What makes General Proximity unique

  • OmniTAC platform uses unbiased Effectome scanning for mechanism-agnostic proximity therapeutics.
  • Targets undruggable proteins in oncology, cardiometabolic, neurodegeneration, and longevity diseases.
  • Team delivered 40+ FDA-approved medicines, 175+ INDs, and 240 patents.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at General Proximity who can refer or advise you

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

11%
Business News Today
Nov 12th, 2025
General Proximity inks Daiichi Sankyo deal to push precision small molecules into oncology

General Proximity inks Daiichi Sankyo deal to push precision small molecules into oncology. General Proximity partners with Daiichi Sankyo to develop proximity-based cancer drugs using OmniTAC. Discover how this biotech is redefining drug discovery. General Proximity, a San Francisco-based biotechnology company developing proximity-induced medicines, has signed a strategic multi-target collaboration with Daiichi Sankyo Co., Ltd. to co-develop cancer treatments using its proprietary OmniTAC discovery platform. The partnership, routed through the Daiichi Sankyo Research Institute in Boston, will focus on identifying first-in-class therapeutic candidates capable of modulating proteins traditionally viewed as "undruggable" in oncology.

VC News Daily
Jan 3rd, 2025
General Proximity Raises $16M Funding

General Proximity, a biotech platform company, has emerged from stealth with $16M in funding. The oversubscribed seed round was led by Aydin Senkut of Felicis, with participation from Y Combinator, age1, Modi Ventures, Wilson Sonsini, and angel investors like Jeff Dean and Ben Mann. The funds will accelerate the development of treatments targeting undruggable proteins related to cancer, cardiometabolic disease, neurodegeneration, and longevity.

PR Newswire
Jan 3rd, 2025
General Proximity Raises $16M for Undruggable Targets

General Proximity has emerged from stealth with $16M to develop treatments for undruggable proteins linked to cancer, cardiometabolic disease, neurodegeneration, and longevity using its OmniTAC platform. The $8M seed round was led by Aydin Senkut at Felicis. Other investors include Y Combinator and Jim Dahl. The company aims to revolutionize drug discovery with a potential market exceeding $250 billion annually.

CALÓ News
Jan 3rd, 2025
General Proximity De-Stealths with $16M to Pioneer Next-Gen Induced Proximity Medicines for 'Undruggable' Targets

SAN FRANCISCO, Jan. 3, 2025 /PRNewswire/ - General Proximity, a breakthrough biotech platform company, today announced its emergence from stealth, unveiling its proprietary OmniTAC platform designed to pioneer the next generation of induced proximity medicines.

VentureCapital.com
Jan 3rd, 2025
General Proximity Unveils OmniTAC Platform with $16M Seed Funding

Biotech platform General Proximity has emerged from stealth mode, securing $16 million in seed funding to drive the development of induced proximity medicines targeting undruggable proteins.